Back to Agenda
Behavioral and Educational Strategies for Avoiding Falsified Medicine Exposure (BE SAFE)
Session Chair(s)
Lubna Merchant, PharmD, MS
Director, Risk Management Center of Excellence
Pfizer Inc , United States
Counterfeit drugs are important public health concern that impact both developed and LMICs. The session is to understand the current landscape and global impact of these and hear from industry, regulators and others on best approaches to address this
Learning Objective : Discuss the significance and current landscape of counterfeit (falsified) medicines; Describe the economic, socio-economic and pervasive health threats to the global population from counterfeit products; Identify the current interventions implemented by regulators, industry, policy makers to combat this; Recognize new approaches to develop more focused programs that address the root cause.
Speaker(s)
Academic Update
Saifuddin Ahmed, MD, PhD
Johns Hopkins University, United States
Professor, Department of Population, Family, and Reproductive Health
WHO Update
Rutendo Kuwana, RPh
World Health Organization (WHO), Switzerland
Team Lead, Incidents and Substandard/Falsified Medical Products
FDA Update
Sangeeta Chatterjee
FDA, United States
Deputy Office Director, Office of Drug Security, Integrity, Response, OC, CDER
Patient Perspective
Regina Mariam Kamoga, MPA
Community Health And Information Network ( CHAIN), Uganda
Executive Director
Have an account?